PHASE II TRIAL OF HYD-SULFATE AZD6244 [NSC 748727] IN PATIENTS WITH BRAF OR NRAS MUTATED MELANOMAS (NCI 8252).
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2015
At a glance
- Drugs Selumetinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.